HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Anderson, H. H. Articles by Contopoulos, A. N. Search for Related Content PubMed PubMed Citation Articles by Anderson, H. H. Articles by Contopoulos, A. N.

Fumagillin in Amebiasis¹

Fumagillin, orally, is active directly against E. histolytica in macaques and man. In man, at a total dosage of 100 mgm. over 12 days, 9 of 10 cyst passers remained clear during 3 months; 50 mgm. total cleared only 4 of 10 patients. In monkeys, total dosage of 250–625 mgm./Kg. over 5 to 10 days was required to keep 12 of 19 animals cleared during 3 months.

No signs nor symptoms of intolerance were noted in man. In monkeys, one showed retention of sulfobromophthalein while another had increased blood urea nitrogen after therapy.

Other laboratory findings were not significant in either monkeys or man. Nonpathogenic intestinal parasites did not clear consistently in either mammalian species. There was close correlation between results in monkeys and man generally.

A comparative study with untreated controls and with terramycin and thiocarbarsone treated patients was made. Fumagillin was most potent and appeared to be most active in chronic, drug refractive, intestinal amebiasis.

¹ Received for publication November 17, 1951.

² With the technical assistance of Mrs. Betty Mythen, Miss Dorothy Swanman and Mr. Aram Demirjian.